ELRIG Announces Drug Discovery 2015 Programme
News Jun 25, 2015
ELRIG’s Drug Discovery event will feature world class speakers presenting on the latest challenges and advances in early stage and translational drug discovery, and provides scientists an excellent opportunity to network throughout the two days.
As well as the programme of more than 50 scientific presentations, the 2015 event will feature poster sessions, Core Technologies Workshops, SLAS Authors Workshops, an exhibition area with around 100 vendor booths, as well as an Innovation Zone for new and exciting emerging companies and technologies, and a Media Area and Careers Zone.
This year sees the addition of two new scientific sessions, ‘Cell & Gene Therapy’ and ‘New Biologic Drugs & Technologies’, as well as: ‘Innovation in Assay Development & Screening’; ‘Metabolic & Cardiovascular Drug Discovery’; ‘Chemistry Innovation in Lead Discovery’; ‘Target Identification & Validation’; ‘Phenotypic Discovery & Cell Imaging’; and ‘Oncology Drug Targets’.
The Core Technologies Workshops provide a more informal, interactive environment in which to discuss key issues and future directions, coordinated by leaders in their fields. This year the workshops will focus on: ‘Enzymology Applications in Drug Discovery’; ‘Protein:Protein Interaction in Drug Discovery’; ‘Ant-Infectives’; and ‘Future of HTS’.
Plenary keynote speakers at this year’s event are David Thomas, Traffick Therapeutiques, and Professor Tracy Hussell, Manchester Collaborative Centre for Inflammation Research. An interview with Prof. Hussell can be found here. Keynote speakers for the four session tracks include: Stephen Rees, AstraZeneca; Dr Chris Torrance, PhoreMost Ltd; Gerard Drewes, Cellzome; Stefano Pluchino , Wellcome Trust-MRC Stem Cell Institute, University of Cambridge (UK); Chas Bountra, SGC, University of Oxford; Philipp Holliger , MRC Laboratory of Molecular Biology; Damian Young, Baylor College of Medicine; and Daniel P. Kelly, Sanford-Burnham Medical Research Institute at Lake Nona.
GlaxoSmithKline plc (GSK) has launched a five-year, $67 million collaboration with the San Francisco and Berkeley campuses of the University of California to build a state-of-the-art laboratory. The goal is to use CRISPR technologies to explore how genes cause disease and to rapidly accelerate the discovery of new drugs.
Scientists have tried developing scaffolds or structures from various materials, including plastic and textile fibers, to lay a foundation for new cells. Duke scientists now describe a more organic model – a scaffold derived from a pig’s meniscus, which performed better in lab tests than healing without a scaffold.READ MORE